KRAS and non-small cell lung carcinoma: A systematic review of 22 studies with 10 564 NSCLC patients demonstrated that ALK was associated with a twofold increased risk of VTE (RR 1.97, 95% CI: 1.54–2.52), whereas EGFR (RR 0.97, 95% CI: 0.69–1.34, P = 0.83) or KRAS mutations (RR 1.27, 95% CI: 0.80–2.02, P = 0.32) were not associated with VTE [54,55].